We are live on ! Find out more
ITOS

iTeos Therapeutics
ITOS

Delisted

ITOS was delisted on the 28th of August, 2025.

Back to rankings

146 hedge funds and large institutions have $704M invested in iTeos Therapeutics in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 52 increasing their positions, 45 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more call options, than puts

Call options by funds: $1.01M | Put options by funds: $461K

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

27% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 15

16% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 45

2% more funds holding

Funds holding: 143 → 146 (+3)

1% more capital invested

Capital invested by funds: $699M → $704M (+$4.97M)

1.4% less ownership

Funds ownership: 103.14% → 101.74% (-1.4%)

Holders
146
Holders Change
+3
Holders Change %
+2.1%
% of All Funds
2.35%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
19
Increased
52
Reduced
45
Closed
15
Calls
$1.01M
Puts
$461K
Net Calls
+$553K
Net Calls Change
+$352K

Top Buyers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
+$8.7M
2
BlackRock
BlackRock
New York
+$3.17M
3
6CM
683 Capital Management
New York
+$2.93M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$2.88M
5
Millennium Management
Millennium Management
New York
+$2.66M

Top Sellers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
-$14.1M
2
PHS
PFM Health Sciences
California
-$9.13M
3
State Street
State Street
Massachusetts
-$7.24M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$4.66M
5
Ameriprise
Ameriprise
Minnesota
-$3.45M
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
26
Barclays
United Kingdom
$4.98M +$647K +33,118 +15%
Northern Trust
27
Northern Trust
Illinois
$4.95M +$232K +11,874 +5%
BCM
28
Bridgeway Capital Management
Texas
$4.76M – – –
Citigroup
29
Citigroup
New York
$4.58M -$1.17M -59,957 -20%
Axa
30
Axa
France
$4.28M -$23.2K -1,186 -0.5%
TCM
31
Tang Capital Management
California
$4.23M -$14.1M -720,800 -77%
AQR Capital Management
32
AQR Capital Management
Connecticut
$3.95M -$3.1M -158,538 -44%
Charles Schwab
33
Charles Schwab
California
$3.56M +$84.5K +4,322 +2%
American Century Companies
34
American Century Companies
Missouri
$3.37M -$972K -49,766 -22%
Principal Financial Group
35
Principal Financial Group
Iowa
$3.1M -$208K -10,661 -6%
Wellington Management Group
36
Wellington Management Group
Massachusetts
$2.94M +$550K +28,134 +23%
BBA
37
Baker Bros. Advisors
New York
$2.94M – – –
6CM
38
683 Capital Management
New York
$2.93M +$2.93M +150,000 New
Prudential Financial
39
Prudential Financial
New Jersey
$2.85M +$23.4K +1,200 +0.8%
Massachusetts Financial Services
40
Massachusetts Financial Services
Massachusetts
$2.42M +$51.2K +2,622 +2%
Ameriprise
41
Ameriprise
Minnesota
$2.38M -$3.45M -176,346 -59%
Allspring Global Investments
42
Allspring Global Investments
North Carolina
$2.12M +$773K +39,569 +57%
Rafferty Asset Management
43
Rafferty Asset Management
New York
$2.01M -$458K -23,435 -19%
DCM
44
DAFNA Capital Management
California
$1.92M +$19.5K +1,000 +1%
UBS Group
45
UBS Group
Switzerland
$1.77M +$450K +23,027 +34%
N
46
Nuveen
North Carolina
$1.75M -$209K -10,676 -11%
Los Angeles Capital Management
47
Los Angeles Capital Management
California
$1.72M +$7.27K +372 +0.4%
AP
48
Advisors Preferred
Maryland
$1.69M +$1.78M +90,973 New
Man Group
49
Man Group
United Kingdom
$1.67M -$602K -30,823 -26%
Deutsche Bank
50
Deutsche Bank
Germany
$1.45M +$1.13M +57,633 +352%
1
2
3 4 5

ITOS Hedge Fund Activity: Q4 2022 in Review

146 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q4 2022, worth a combined $704M — up 0.71% from $699M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ITOS positions and 15 closed out — a net gain of 4 holders — while 52 added to existing stakes and 45 trimmed.

The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $8.7M. The largest seller was Tang Capital Management, cutting an estimated $14.1M.

  • 146 institutional investors held iTeos Therapeutics (ITOS) as of Q4 2022, up from 143 in Q3 2022.
  • Funds reported $704M of iTeos Therapeutics stock for Q4 2022, up 0.71% quarter-over-quarter.
  • 19 funds opened new iTeos Therapeutics positions in Q4 2022 and 15 closed out, a net change of +4 holders.
  • The largest iTeos Therapeutics buyer in Q4 2022 was Octagon Capital Advisors, an estimated $8.7M added.
  • The largest iTeos Therapeutics seller in Q4 2022 was Tang Capital Management, an estimated $14.1M sold.

Based on aggregated 13F filings for Q4 2022.